Within a week, Actelion has announced both Phase II and III trial studies for insomnia and hypertension in children. Even for Europe’s most valuable biotech, this is an impressive period.
Actelion is to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia. The day before this, it also announced a Phase III trial with macitentan (Opsumit) in children with pulmonary arterial hypertension (PAH).
This is even more impressive when you consider that July is the beginning of the ‘low season’ for the Biotech and Pharma industries (and most industries) as the Summer starts. Indeed, announcements in such close succession are usually only around the January boom, when conferences like the J.P. Morgan inspire companies to save their news for release all at once.